Clinical Trial Update: Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating neoadjuvanttislelizumab plus chemotherapy followed by surgery for unresectable stage III non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Beijing Tsinghua Chang Gung Hospital | Conditions: NSCLC, Stage III | Phase 2 | Status: UNKNOWN